Complete pathologic response after two-stage cytoreductive surgery with HIPEC for bulky pseudomyxoma peritonei: proof of concept
Introduction Pseudomyxoma peritonei (PMP) is a rare disease characterized by the progressive accumulation of mucinous ascites and peritoneal implants. The optimal treatment for PMP includes the association of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). For p...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-01-01
|
Series: | International Journal of Hyperthermia |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/02656736.2020.1772511 |
id |
doaj-d15892c88977457f9133a71739f07e7c |
---|---|
record_format |
Article |
spelling |
doaj-d15892c88977457f9133a71739f07e7c2021-08-09T15:50:02ZengTaylor & Francis GroupInternational Journal of Hyperthermia0265-67361464-51572020-01-0137158559110.1080/02656736.2020.17725111772511Complete pathologic response after two-stage cytoreductive surgery with HIPEC for bulky pseudomyxoma peritonei: proof of conceptOlivia Sgarbura0Mohammed Al Hosni1Andrea Petruzziello2Rodrigo Figueroa3Lakhdar Khellaf4Marie-Hélène Pissas5Sébastien Carrère6Stephanie Nougaret7Frédéric Bibeau8François Quénet9Surgical Oncology Department, Montpellier Cancer Institute, University of MontpellierSurgical Oncology Division, Department of Surgery, Sultan Qaboos University HospitalMarcelino Champagnat HospitalSanatorio AllendeUniversity of Medicine Montpellier 2 Rue de l’École de MédecineSurgical Oncology Department, Montpellier Cancer Institute, University of MontpellierSurgical Oncology Department, Montpellier Cancer Institute, University of MontpellierUniversity of Medicine Montpellier 2 Rue de l’École de MédecinePathology Department, Caen University Hospital, University of Caen NormandySurgical Oncology Department, Montpellier Cancer Institute, University of MontpellierIntroduction Pseudomyxoma peritonei (PMP) is a rare disease characterized by the progressive accumulation of mucinous ascites and peritoneal implants. The optimal treatment for PMP includes the association of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). For patients with a large burdensome disease, the completeness of cytoreduction sometimes requires maximal effort surgery. The aim of this article is to provide proof of concept for two stage cytoreductive surgery (CRS) in this category of patients. Methods and materials A two stage CRS and HIPEC with oxaliplatin was proposed for patients with bulky PMP including important involvement of the serosal surfaces of the bowel or colon who had an impaired nutritional status. The residual disease at the end of the first stage was less than 5 mm of thickness on several implants. Clinical, surgical and histopathological variables were analyzed. Results All eight patients completed the two-stage strategy. Mortality was nil. One Clavien Dindo grade 3 event occurred in each stage. After a median follow up of 29.5 months, all patients were alive and free of recurrence. All of the patients had histopathological complete response on the specimens obtained from the residual sites during the second stage surgery. Conclusions Two-stage surgical strategy is feasible for bulky PMP patients and it is associated with little high-grade morbidity and enhanced visceral sparing.http://dx.doi.org/10.1080/02656736.2020.1772511pseudomyxoma peritoneicytoreductive surgeryhyperthermic intraperitoneal chemotherapytwo-stage surgeryoxaliplatin |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Olivia Sgarbura Mohammed Al Hosni Andrea Petruzziello Rodrigo Figueroa Lakhdar Khellaf Marie-Hélène Pissas Sébastien Carrère Stephanie Nougaret Frédéric Bibeau François Quénet |
spellingShingle |
Olivia Sgarbura Mohammed Al Hosni Andrea Petruzziello Rodrigo Figueroa Lakhdar Khellaf Marie-Hélène Pissas Sébastien Carrère Stephanie Nougaret Frédéric Bibeau François Quénet Complete pathologic response after two-stage cytoreductive surgery with HIPEC for bulky pseudomyxoma peritonei: proof of concept International Journal of Hyperthermia pseudomyxoma peritonei cytoreductive surgery hyperthermic intraperitoneal chemotherapy two-stage surgery oxaliplatin |
author_facet |
Olivia Sgarbura Mohammed Al Hosni Andrea Petruzziello Rodrigo Figueroa Lakhdar Khellaf Marie-Hélène Pissas Sébastien Carrère Stephanie Nougaret Frédéric Bibeau François Quénet |
author_sort |
Olivia Sgarbura |
title |
Complete pathologic response after two-stage cytoreductive surgery with HIPEC for bulky pseudomyxoma peritonei: proof of concept |
title_short |
Complete pathologic response after two-stage cytoreductive surgery with HIPEC for bulky pseudomyxoma peritonei: proof of concept |
title_full |
Complete pathologic response after two-stage cytoreductive surgery with HIPEC for bulky pseudomyxoma peritonei: proof of concept |
title_fullStr |
Complete pathologic response after two-stage cytoreductive surgery with HIPEC for bulky pseudomyxoma peritonei: proof of concept |
title_full_unstemmed |
Complete pathologic response after two-stage cytoreductive surgery with HIPEC for bulky pseudomyxoma peritonei: proof of concept |
title_sort |
complete pathologic response after two-stage cytoreductive surgery with hipec for bulky pseudomyxoma peritonei: proof of concept |
publisher |
Taylor & Francis Group |
series |
International Journal of Hyperthermia |
issn |
0265-6736 1464-5157 |
publishDate |
2020-01-01 |
description |
Introduction Pseudomyxoma peritonei (PMP) is a rare disease characterized by the progressive accumulation of mucinous ascites and peritoneal implants. The optimal treatment for PMP includes the association of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). For patients with a large burdensome disease, the completeness of cytoreduction sometimes requires maximal effort surgery. The aim of this article is to provide proof of concept for two stage cytoreductive surgery (CRS) in this category of patients. Methods and materials A two stage CRS and HIPEC with oxaliplatin was proposed for patients with bulky PMP including important involvement of the serosal surfaces of the bowel or colon who had an impaired nutritional status. The residual disease at the end of the first stage was less than 5 mm of thickness on several implants. Clinical, surgical and histopathological variables were analyzed. Results All eight patients completed the two-stage strategy. Mortality was nil. One Clavien Dindo grade 3 event occurred in each stage. After a median follow up of 29.5 months, all patients were alive and free of recurrence. All of the patients had histopathological complete response on the specimens obtained from the residual sites during the second stage surgery. Conclusions Two-stage surgical strategy is feasible for bulky PMP patients and it is associated with little high-grade morbidity and enhanced visceral sparing. |
topic |
pseudomyxoma peritonei cytoreductive surgery hyperthermic intraperitoneal chemotherapy two-stage surgery oxaliplatin |
url |
http://dx.doi.org/10.1080/02656736.2020.1772511 |
work_keys_str_mv |
AT oliviasgarbura completepathologicresponseaftertwostagecytoreductivesurgerywithhipecforbulkypseudomyxomaperitoneiproofofconcept AT mohammedalhosni completepathologicresponseaftertwostagecytoreductivesurgerywithhipecforbulkypseudomyxomaperitoneiproofofconcept AT andreapetruzziello completepathologicresponseaftertwostagecytoreductivesurgerywithhipecforbulkypseudomyxomaperitoneiproofofconcept AT rodrigofigueroa completepathologicresponseaftertwostagecytoreductivesurgerywithhipecforbulkypseudomyxomaperitoneiproofofconcept AT lakhdarkhellaf completepathologicresponseaftertwostagecytoreductivesurgerywithhipecforbulkypseudomyxomaperitoneiproofofconcept AT mariehelenepissas completepathologicresponseaftertwostagecytoreductivesurgerywithhipecforbulkypseudomyxomaperitoneiproofofconcept AT sebastiencarrere completepathologicresponseaftertwostagecytoreductivesurgerywithhipecforbulkypseudomyxomaperitoneiproofofconcept AT stephanienougaret completepathologicresponseaftertwostagecytoreductivesurgerywithhipecforbulkypseudomyxomaperitoneiproofofconcept AT fredericbibeau completepathologicresponseaftertwostagecytoreductivesurgerywithhipecforbulkypseudomyxomaperitoneiproofofconcept AT francoisquenet completepathologicresponseaftertwostagecytoreductivesurgerywithhipecforbulkypseudomyxomaperitoneiproofofconcept |
_version_ |
1721213820475539456 |